Which laboratory tests should be ordered to monitor a patient receiving ongoing testosterone 1.62% gel therapy?

Laboratory Monitoring for Ongoing Testosterone 1.62% Gel Treatment

For patients on ongoing testosterone 1.62% gel therapy, check serum testosterone levels at 3-6 months after initiation and then annually, hematocrit at 3-6 months and annually, and PSA with digital rectal exam at 3-6 months and annually (for men ≥40 years with baseline PSA >0.6 ng/ml). 1

Core Laboratory Tests

Testosterone Level Monitoring

• Timing for transdermal gels: Measure testosterone level any time after the patient has been on treatment for at least 1 week 1
• Target range: Aim for mid-normal range (approximately 400-700 ng/dL)
• Frequency: At 3-6 months after initiation, then annually 1, 2
• Dose adjustment: If testosterone is >700 ng/dL or <400 ng/dL, adjust the dose 1

Hematocrit/Hemoglobin

• Critical monitoring parameter due to dose-dependent increases in hemoglobin with testosterone therapy 1
• Frequency: At 3-6 months, then annually 1, 2
• Action threshold: If hematocrit >54%, stop therapy immediately until it decreases to a safe level; evaluate for hypoxia and sleep apnea; reinitiate with reduced dose 1
• Baseline contraindication: Hematocrit >50% at baseline is a relative contraindication, as these men are more likely to exceed 54% on treatment 1

Prostate Monitoring (Age-Dependent)

For men ≥40 years old with baseline PSA >0.6 ng/ml:

• Perform digital rectal examination (DRE) and PSA at 3-6 months, then follow age- and race-appropriate prostate cancer screening guidelines 1

Obtain urological consultation if:

• PSA increase >1.4 ng/ml within any 12-month period 1
• PSA velocity >0.4 ng/ml/year (using 6-month PSA as reference, applicable if data available >2 years) 1
• Prostatic abnormality detected on DRE 1
• AUA/IPSS symptom score >19 1

Additional Monitoring Considerations

Clinical Assessment

• Evaluate at 3-6 months and annually for symptom response and adverse effects 1, 2
• Assess for formulation-specific adverse effects at each visit, particularly skin reactions at application sites for testosterone gels 1

Optional/Conditional Tests

• Bone mineral density: Consider after 1-2 years in hypogonadal men with osteoporosis or low-trauma fracture 1
• Liver function tests and lipid profile: Monitor periodically per FDA labeling 3

Critical Safety Points

The hematocrit threshold of 54% is non-negotiable - testosterone must be stopped at this level due to potential thromboembolic risk, though notably no testosterone-associated thromboembolic events had been reported in the literature at the time of guideline publication 4. The risk is higher with injectable formulations compared to transdermal preparations 4.

PSA monitoring remains controversial but the 2010 Endocrine Society guidelines recommend it for men ≥40 years with baseline PSA >0.6 ng/ml, with specific thresholds for urological referral 1. The combination of PSA and DRE improves prostate cancer detection compared to either test alone 1.

For testosterone gel specifically, the timing of testosterone measurement is flexible (any time after 1 week of treatment) unlike injectable formulations that require specific timing relative to injection 1. This reflects the more stable pharmacokinetics of transdermal delivery.